Influenza Treatment Market Forecast To Reach $8.19 Billion By 2030: Key Trends Explained
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Influenza Treatment Market Set To Climb From $7.1 Billion In 2026 To $8.19 Billion By 2030
The influenza treatment market has experienced consistent growth in recent years. Its valuation is anticipated to increase from $6.83 billion in 2025 to $7.1 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.0%. This historical expansion can be linked to recurring seasonal influenza outbreaks worldwide, the established clinical effectiveness of neuraminidase inhibitors, the widespread availability of antiviral drugs through pharmacies, a public health focus on minimizing influenza complications, and the long-standing hospital utilization of antiviral treatments.
The influenza treatment market size is anticipated to experience consistent expansion over the next few years. This market is projected to reach a valuation of $8.19 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 3.6%. The projected increase is due to several factors such as the increasing occurrence of both seasonal and pandemic influenza strains, heightened awareness regarding the advantages of prompt influenza treatment, an expanding elderly demographic susceptible to severe influenza, improved availability of antiviral medications, and a continuous requirement for quick management of flu symptoms. Key trends expected during this period encompass the sustained application of antiviral therapies for managing seasonal influenza, a rising inclination towards starting antiviral treatment early, greater uptake of single-dose and shorter-duration antiviral regimens, an increasing need for oral influenza treatment alternatives, and ongoing dependence on existing antiviral molecules during flu epidemics.
Get A Free Sample Report With In-Depth Market Insights:
Influenza Treatment Market Growth Catalysts And Demand Drivers
The increasing occurrence of contagious respiratory illnesses is anticipated to drive the expansion of the influenza treatment market in the coming years. These illnesses encompass infectious conditions such as influenza, measles, and respiratory syncytial virus (RSV), which transmit through contact with infected individuals, respiratory droplets, contaminated surfaces, or shared objects. The prevalence of contagious respiratory illnesses is rising due to factors including higher population densities, inadequate healthcare infrastructure, misuse of antibiotics, and increased international travel. The influenza treatment market supports the management of respiratory infections by providing antiviral therapies and vaccines used to treat and prevent illnesses like influenza, COVID-19, and other respiratory viral infections. For instance, in September 2023, the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, reported that RSV-related hospitalizations rose from 2 hospitalizations per 100,000 people during the week ending August 5, 2023, to 7 hospitalizations per 100,000 people by the week ending August 19, 2023. Thus, the heightened prevalence of contagious respiratory illnesses is propelling the growth of the influenza treatment market.
Influenza Treatment Market Segment Breakdown: Which Categories Lead On Revenue?
The influenza treatment market covered in this report is segmented –
1) By Product Type: Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, Other Products
2) By Route Of Administration: Oral, Other Routes Of Administration
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels
Subsegments:
1) By Peramivir: Intravenous Peramivir, Peramivir Injection
2) By Zanamivir: Inhaled Zanamivir, Zanamivir Diskhaler
3) By Oseltamivir Phosphate: Oseltamivir Capsules, Oseltamivir Oral Suspension
4) By Baloxavir Marboxil: Baloxavir Tablets, Baloxavir Granules For Oral Suspension
5) By Other Products: Rimantadine, Amantadine
Influenza Treatment Market Trends Shaping Long-Term Demand
Leading companies in the influenza treatment market are concentrating on developing innovative solutions, such as trivalent inactivated influenza vaccines, to bolster immune protection and prevent seasonal flu outbreaks. These trivalent inactivated influenza vaccines are flu shots that incorporate three killed virus strains, designed to offer defense against the most common influenza viruses each season. For example, in September 2025, Zydus Lifesciences Limited, an India-based pharmaceutical company, introduced VaxiFlu, India’s first trivalent influenza vaccine, in alignment with WHO’s global recommendations. VaxiFlu is approved for individuals aged six months and above, containing updated WHO-recommended virus strains (A/H1N1, A/H3N2, and a B/Victoria lineage) to ensure seasonal relevance, while intentionally excluding the B/Yamagata lineage, which has not circulated widely in recent years. This vaccine’s formulation enables precision-targeted vaccination, thereby reducing unnecessary antigen exposure and improving safety profiles compared to earlier quadrivalent formulations. Furthermore, this method is consistent with public health strategies in countries where B/Yamagata lineage viruses are no longer prevalent.
Influenza Treatment Market Leading Players And Competitive Positioning
Major companies operating in the influenza treatment market are F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Takeda Pharmaceutical Company, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Cipla Ltd, Dr. Reddy’s Laboratories Ltd., Lupin Limited, NATCO Pharma Limited, Aurobindo Pharma Limited, Zydus Lifesciences Limited, Torrent Pharmaceuticals Ltd., Hetero Drugs Limited, BioCryst Pharmaceuticals Inc., NanoViricides Inc., Shionogi & Co. Ltd., Chugai Pharmaceutical Co. Ltd., Alkem Laboratories Limited
View The Full Influenza Treatment Market Report:
Influenza Treatment Market Top Region By Revenue And Market Share
North America was the largest region in the influenza treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
